Citius Pharma (CTXR) to Merge Subsidiary, with Publicly Traded SPAC TenX Keane (TENK). Shares...
We Would Define This as Huge News..
Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership...
Ohio State University Completes Study on Pressure Bioscience (PBIO) and Protein Drinks.
Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market.
Recent Study Published by The Ohio...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at real fireworks in the coming year....
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our Favorite.
We launched the Psychedelic Stock Review...
With Help of Sanofi (SNY), Dario Health (DRIO) Builds Scientific Case for Its Diabetes...
We always find it Interesting when a Company with a $130 billion market cap (Sanofi: SNY), teams up with a Company with a $80...
Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.
Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs.
Starting Due Diligence Now.
It takes us about 15 minutes after talking...
CEO Interview: Ric Schumacher Pressure Bioscience (PBIO).
https://youtu.be/a8d1bawmMQk
RELATED: Adding Pressure BioSciences (PBIO) $0.80 to Watch List
Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced...
Adding Pressure BioSciences (PBIO) $0.80 to Watch List.
Long Time Coming, Pressure Bio Reaches Turning Point. Science Finally Meets Revenues.
Photo Ric Schumacher CEO
SHORT TERM CHART
LIVE QUOTE
When we say "finally" meets revenues, that's...















